Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD

Inclusion Criteria: * Patients aged \> 18 * Age of disease onset \< 70 years * Clinical and biological diagnosis of AD based on * Progressive amnestic syndrome associated or not with other cognitive impairments * Biological criteria: CSF biomarkers suggestive of AD. * Brain MRI congruent with the diagnosis, left to the appreciation of the investigator * CDR (Clinical Dementia Rating Scale) = 0.5 or 1 * If patients have an antidepressant or acetylcholinesterase inhibitors treatment, patients must be treated with stable doses of treatment for at least 1 month before inclusion. * Have a caregiver who provides a separate written informed consent to participate. If a caregiver/study informant cannot continue, one replacement is allowed. * Have adequate vision and hearing for neuropsychological testing in the opinion of the investigator. * Have given written informed consent approved by the ethical review board (ERB) governing the site. * The patient has to have a French social security number and be fluent and literate in French. Exclusion Criteria: * Subject with a psychiatric evolutionary and/or badly checked. * Subject with a grave, severe or unstable pathology (left to the judgement of the investigator) the nature of which can interfere with the variables of evaluation. * Epileptic subjects * Subject under guardianship or curatorship * Subject presenting contraindications to the MRI * Known or supposed history (\< or = 5 years) of severe alcoholism or misuse of drugs *…